Tocilizumab improved both clinical and laboratory manifestations except for interleukin-18 in a case of multiple drug-resistant adult-onset Still's disease

Internal Medicine

Volumn 50, Issue 16, 2011, Pages 1757-1760

  Yoshida, Yoshihiro ^a   Sakamoto, Mayuko ^a   Yokota, Kazuhiro ^a   Sato, Kojiro ^a   Mimura, Toshihide ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Adult onset Still's disease; IL 18; IL 6; Tocilizumab

Indexed keywords

ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; C REACTIVE PROTEIN; CYCLOSPORIN A; ETANERCEPT; FERRITIN; HEMOGLOBIN; INFLIXIMAB; INTERLEUKIN 18; LACTATE DEHYDROGENASE; METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE; STROMELYSIN; TACROLIMUS; TOCILIZUMAB;

ADULT; ADULT ONSET STILL DISEASE; ARTICLE; CASE REPORT; CLINICAL FEATURE; DOSE RESPONSE; DOWN REGULATION; DRUG DOSE INCREASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FATIGUE; FEVER; HUMAN; KNEE ARTHRITIS; LEUKOCYTE COUNT; LEUKOCYTOSIS; MALE; MULTIDRUG RESISTANCE; OUTCOME ASSESSMENT; PATHOGENESIS; RASH; THROMBOCYTE COUNT; TOTAL QUALITY MANAGEMENT; UPREGULATION;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL MARKERS; DRUG RESISTANCE, MULTIPLE; HUMANS; INTERLEUKIN-18; MALE; STILL'S DISEASE, ADULT-ONSET;

EID: 84860389644     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.50.4771     Document Type: Article

References (23)

1. Bywaters EG. Still's disease in the adult. Ann Rheum Dis 30: 121-133, 1971.
2. Colebunders R, Stevens WJ, Vanagt E, Snoeck J. Adult Still's diseasev caused by Yersinia enterocolitica infection. Arch Intern Med 144: 1880-1882, 1984.
3. Wouters JM, van der Veen J, van de Putte LB, de Rooij DJ. Adult onset Still's disease and viral infections. Ann Rheum Dis 47: 764-767, 1988.
4. Masson C, Le Loet X, Liote F, et al. Adult Still's disease. Part II. Management, outcome, and prognostic factors. Rev Rhum Engl Ed 62: 758-765, 1995.
5. Fautrel B, Borget C, Rozenberg S, et al. Corticosteroid sparing effect of low dose methotrexate treatment in adult Still's disease. J Rheumatol 26: 373-378, 1999.
6. Marchesoni A, Ceravolo GP, Battafarano N, Rossetti A, Tosi S, Fantini F. Cyclosporin A in the treatment of adult onset Still's disease. J Rheumatol 24: 1582-1587, 1997.
7. Kraetsch HG, Antoni C, Kalden JR, Manger B. Successful treatment of a small cohort of patients with adult onset of Still's disease with infliximab: first experiences. Ann Rheum Dis 60 (Suppl 3): iii55-iii57, 2001.
8. Kokkinos A, Iliopoulos A, Greka P, Efthymiou A, Katsilambros N, Sfikakis PP. Successful treatment of refractory adult-onset Still's disease with infliximab. A prospective, non-comparative series of four patients. Clin Rheumatol 23: 45-49, 2004.
9. Fautrel B, Sibilia J, Mariette X, Combe B. Tumour necrosis factor alpha blocking agents in refractory adult Still's disease: an observational study of 20 cases. Ann Rheum Dis 64: 262-266, 2005.
10. Husni ME, Maier AL, Mease PJ, et al. Etanercept in the treatment of adult patients with Still's disease. Arthritis Rheum 46: 1171-1176, 2002.
11. Kotter I, Wacker A, Koch S, et al. Anakinra in patients with treatment-resistant adult-onset Still's disease: four case reports with serial cytokine measurements and a review of the literature. Semin Arthritis Rheum 37: 189-197, 2007.
12. Nishimoto N, Sasai M, Shima Y, et al. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 95: 56-61, 2000.
13. Yokota S, Miyamae T, Imagawa T, Katakura S, Kurosawa R, Mori M. Clinical study of tocilizumab in children with systemic-onset juvenile idiopathic arthritis. Clin Rev Allergy Immunol 28: 231-238, 2005.
14. Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 112: 3959-3964, 2008.
15. Holt I, Cooper RG, Hopkins SJ. Relationships between local inflammation, interleukin-6 concentration and the acute phase protein response in arthritis patients. Eur J Clin Invest 21: 479-484, 1991.
16. Uchiyama Y, Yoshida H, Koike N, et al. Anti-IL-6 receptor antibody increases blood IL-6 level via the blockade of IL-6 clearance, but not via the induction of IL-6 production. Int Immunopharmacol 8: 1595-1601, 2008.
17. Kishida D, Okuda Y, Onishi M, et al. Successful tocilizumab treatment in a patient with adult-onset Still's disease complicated by chronic active hepatitis B and amyloid A amyloidosis. Mod Rheumatol 21: 215-218, 2011.
18. Kobayashi M, Takahashi Y, Yamashita H, Kaneko H, Mimori A. Benefit and a possible risk of tocilizumab therapy for adult-onset Still's disease accompanied by macrophage-activation syndrome. Mod Rheumatol 21: 92-96, 2011.
19. Yoshimura M, Makiyama J, Koga T, et al. Successful treatment with tocilizumab in a patient with refractory adult-onset Still's disease (AOSD). Clin Exp Rheumatol 28: 141-142, 2010.
20. Sumida K, Ubara Y, Hoshino J, et al. Etanercept-refractory adultonset Still's disease with thrombotic thrombocytopenic purpura successfully treated with tocilizumab. Clin Rheumatol 29: 1191-1194, 2010.
21. Matsumoto K, Nagashima T, Takatori S, et al. Glucocorticoid and cyclosporine refractory adult onset Still's disease successfully treated with tocilizumab. Clin Rheumatol 28: 485-487, 2009.
22. Nakahara H, Mima T, Yoshio-Hoshino N, Matsushita M, Hashimoto J, Nishimoto N. A case report of a patient with refractory adult-onset Still's disease who was successfully treated with tocilizumab over 6 years. Mod Rheumatol 19: 69-72, 2009.
23. Murakami K, Fujii T, Yukawa N, et al. Successful treatment of a patient with refractory adult Still's disease by tacrolimus. Mod Rheumatol 17: 167-170, 2007.